CSF2 and non-small cell lung carcinoma: In the phase I/II CTN-2000 trial, Brunsvig and colleagues [49] treated 26 patients affected by non-small cell lung cancer (NSCLC) with GV1001 in combination with p540 hTERT peptide and GM-CSF.